[Treatment of chromoblastomycosis and phaeohyphomycosis]

Klin Mikrobiol Infekc Lek. 2020 Jun;26(2):62-68.
[Article in Czech]

Abstract

Cases of chromoblastomycosis are frequent in certain parts of the world, especially in some developing countries. Clinical manifestations of chromoblastomycosis are typical. To a certain extent, pathogens causing chromoblastomycosis overlap with those causing phaeohyphomycosis. Although cases of phaeohyphomycosis are not very common, they may end fatally. Therefore early management of these life-threatening infections is rather important. Targeted antifungal therapy and surgery are effective in combating these infections. Recently, several triazole antifungals such as posaconazole and isavuconazole have been available to treat even the most severe cases. Prevention of the infection should be aimed at reducing the risk of subcutaneous trauma, particularly in persons in contact with potential sources of infection such as wood materials important from endemic areas.

MeSH terms

  • Antifungal Agents / therapeutic use*
  • Chromoblastomycosis* / diagnosis
  • Chromoblastomycosis* / drug therapy
  • Humans
  • Nitriles
  • Phaeohyphomycosis* / diagnosis
  • Phaeohyphomycosis* / drug therapy
  • Pyridines
  • Triazoles

Substances

  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Triazoles
  • isavuconazole
  • posaconazole